Cloud-Clone Corp.

APA030Hu61 100µg Active Factor Related Apoptosis (FAS) Organism Species: *Homo sapiens (Human) Instruction manual* 

FOR RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1st Edition (Apr, 2016)

#### [PROPERTIES]

Source: Eukaryotic expression. Host: 293F cell Residues: Gln26~Asn173 Tags: N-terminal His-tag Purity: >95% Endotoxin Level: <1.0EU per 1µg (determined by the LAL method). Buffer Formulation: PBS, pH7.4, containing 5% trehalose. Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 6.7 Predicted Molecular Mass: 18.5kDa Accurate Molecular Mass: 22&25&27kDa as determined by SDS-PAGE reducing conditions.

# [ <u>USAGE</u> ]

Reconstitute in 10mM PBS (pH7.6) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

#### [ STORAGE AND STABILITY ]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the

# Cloud-Clone Corp.

protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

### [SEQUENCE]

QVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSN

# [ACTIVITY]

FAS (Tumor necrosis factor receptor superfamily member 6) belongs to the tumor necrosis factor receptor superfamily. FAS contains a death domain, which has been shown to play a central role in the physiological regulation of programmed cell death. A binding ELISA assay was conducted to detect the association of FAS with FASL. Briefly, FASL were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul FASL were then transferred to FAS-coated microtiter wells and incubated for 1h at 37 °C. Wells were washed with PBST and incubated for 1h with anti-FASL pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 °C. Finally, add 50 µL stop solution to the wells and read at 450nm immediately. The binding activity of FAS and FASL was shown in Figure 1, and this effect was in a dose dependent manner, the EC50 was approximately 0.044 ug/mL.

Cloud-Clone Corp.



Figure 1. The binding activity of FAS with FASL

#### [IDENTIFICATION]



Figure 2. SDS-PAGE

Sample: Active recombinant FAS, human

#### [<u>IMPORTANT NOTE</u>]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.